Galapagos NV (GLPGF)
OTCMKTS · Delayed Price · Currency is USD
34.00
0.00 (0.00%)
Feb 11, 2026, 4:00 PM EST
Galapagos NV Revenue
Galapagos NV had revenue of 71.16M EUR in the quarter ending September 30, 2025, with 18.90% growth. This brings the company's revenue in the last twelve months to 286.92M, up 10.31% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm)
286.92M EUR
Revenue Growth
+10.31%
P/S Ratio
6.60
Revenue / Employee
514.20K EUR
Employees
558
Market Cap
2.22B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
| Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
| Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
| Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
| Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
| Dec 31, 2019 | 834.90M | 556.24M | 199.61% |
| Dec 31, 2018 | 278.67M | 151.58M | 119.27% |
| Dec 31, 2017 | 127.09M | -2.43M | -1.88% |
| Dec 31, 2016 | 129.52M | 89.96M | 227.37% |
| Dec 31, 2015 | 39.56M | -29.81M | -42.97% |
| Dec 31, 2014 | 69.37M | 69.29M | 90,429.20% |
| Dec 31, 2013 | 76.63K | -136.19M | -99.94% |
| Dec 31, 2012 | 136.27M | 42.80M | 45.79% |
| Dec 31, 2011 | 93.47M | -20.67M | -18.11% |
| Dec 31, 2010 | 114.14M | 21.05M | 22.62% |
| Dec 31, 2009 | 93.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Arch Biopartners | 198.11K |
Galapagos NV News
- 5 weeks ago - Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities - GlobeNewsWire
- 7 weeks ago - Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation - Seeking Alpha
- 2 months ago - GLPG Crosses Above Average Analyst Target - Nasdaq
- 2 months ago - Galapagos (GLPG) Showcases Promising Phase 2 Results for CAR T-Cell Therapy - GuruFocus
- 2 months ago - Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025 - GlobeNewsWire
- 2 months ago - Galapagos Receives Transparency Notifications from Bank of America - GlobeNewsWire
- 3 months ago - RBC Capital Raises Price Target for GLPG to $32. ... - GuruFocus
- 3 months ago - Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript - Seeking Alpha